- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))
Compound class: Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
|Mogamulizumab is a CCR4-targeted immuno-oncology drug. It is intended to deplete CCR4-expressing Treg cells in the tumour microenvironment so as to release of Teff cells from Treg-mediated suppression, and facilitate tumour cell killing. However, it also targets extratumoural Treg cells that serve other vital immune cell functions, and can induce serious side effects such as dermatologic toxicity and autoimmune issues [2-3].|
|Adult T-cell leukemia||
||An anti-CCR4 monoclonal antibody approved for relapsed or refractory adult T-cell leukemia/lymphoma.|
|Cutaneous T cell lymphoma||
||Approved drug for two subtypes of cutaneous lymphoma: mycosis fungoides or Sézary syndrome- FDA 2018.|